Recombinant Human CD38 protein, hFc-tagged

• Cat.No.: CD38-4996H
• Product Overview: Recombinant Human CD38 protein(P28907-1)(Val43-Ile300), fused with C-terminal hFc tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: C-hFc
• Protein length: Val43-Ile300
• Form: Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.
• Bio-activity: Immobilized Human CD38, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-CD38 Antibody, hFc Tag with the EC50 of 24.8ng/ml determined by ELISA.
• Molecular Mass: The protein has a predicted MW of 56.6 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.
• Endotoxin: Less than 1EU per μg by the LAL method.
• Purity: > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
• Storage: Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• Reconstitution: Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Gene Information

• Gene Name: CD38 CD38 molecule [ Homo sapiens ]
• Official Symbol: CD38
• Synonyms: CD38; CD38 molecule; CD38 antigen (p45); ADP-ribosyl cyclase 1; ADP ribosyl cyclase 1; NAD(+) nucleosidase; cADPr hydrolase 1; cyclic ADP-ribose hydrolase 1; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase; T10
• Gene ID: 952
• mRNA Refseq: NM_001775
• Protein Refseq: NP_001766
• MIM: 107270
• UniProt ID: P28907

Reviews

01/15/2021

By employing this protein reagent, I can swiftly obtain sufficient protein samples, meeting the high demand for experiments.

06/11/2019

The consumable costs associated with this protein reagent are relatively low, rendering it economically feasible and efficient for large-scale applications in the laboratory.

06/08/2019

A magical partner in experimentation, taking your research to new heights.

Q&As

What are the challenges and future directions in CD38 research?

 CD38 research faces several challenges and offers exciting future directions. One challenge is deciphering the precise molecular mechanisms by which CD38 modulates cellular processes and interacts with other proteins. Additionally, understanding the context-dependent functions of CD38 in different cell types and disease conditions requires further investigation. Future directions include exploring the therapeutic potential of CD38 inhibitors in combination with other treatment modalities, investigating the role of CD38 in the tumor microenvironment, and advancing our understanding of the dynamic regulation of CD38 expression and activity. Such advancements will pave the way for personalized medicine approaches targeting CD38 in various diseases.

What are the functions and mechanisms of protein CD38 in biological systems?

Protein CD38 is a transmembrane enzyme that plays a crucial role in various biological processes. Its main function is the hydrolysis of NAD+ to generate ADP-ribose, leading to the production of cyclic ADP-ribose (cADPR) and ADP-ribose (ADPR) as intracellular calcium signaling molecules. CD38 is involved in regulating cell proliferation, apoptosis, and immune responses. Its mechanisms of action include modulation of intracellular signaling pathways, such as cADPR-mediated calcium release and involvement in apoptotic pathways through ADPR.

Does CD38 interact with other proteins or signaling pathways?

Yes, CD38 exhibits interactions with several proteins and signaling pathways. For instance, CD38 is involved in the regulation of calcium signaling by interacting with calcium channels and receptors. It also interacts with other proteins in the NAD+ metabolism pathway, such as NAD+-consuming enzymes and NAD+ synthesizing enzymes. Furthermore, CD38 can modulate immune responses by interacting with immune cell receptors and co-stimulatory molecules. Understanding these protein-protein interactions and their functional consequences is essential for comprehending the broader role of CD38 in cellular processes and disease pathogenesis.

What are the current areas of research focus regarding CD38?

Current research on CD38 encompasses various aspects. One area of focus is elucidating the role of CD38 in disease pathogenesis, including its involvement in cancer progression, autoimmune disorders, and neurodegenerative diseases. Researchers are also investigating the potential of CD38 as a diagnostic and prognostic marker in different diseases. Additionally, efforts are being made to identify novel therapeutic targets within the CD38 signaling pathway and develop more effective and specific CD38 inhibitors. Understanding the complex regulatory mechanisms and functional consequences of CD38 will contribute to the development of targeted therapies and precision medicine approaches.

Are there any genetic variations or polymorphisms associated with CD38 expression or function?

Yes, genetic variations in the CD38 gene have been identified, and some of these variations have been associated with altered CD38 expression or function. For example, certain single nucleotide polymorphisms (SNPs) in the CD38 gene have been linked to changes in CD38 enzyme activity and NAD+ metabolism. These genetic variations can influence immune responses, susceptibility to certain diseases, and response to therapies targeted at CD38.

In which cell types is CD38 expressed and considered important?

CD38 is widely expressed in various cell types, including immune cells (such as lymphocytes, monocytes, dendritic cells, etc.), neuronal cells, endothelial cells, and several others. It is especially important in immune cells, where it plays a critical role in immune responses, such as T cell activation, B cell differentiation, and antibody production. CD38 expression in neuronal cells has been linked to neurotransmitter release and synaptic plasticity. Additionally, CD38 expression in endothelial cells is associated with regulating vascular function and inflammation.

What are the potential therapeutic implications of targeting CD38?

Targeting CD38 has gained significant attention in the development of therapeutic strategies. CD38 inhibitors, such as monoclonal antibodies, have shown promising results in the treatment of hematological malignancies, particularly multiple myeloma. These inhibitors block CD38 enzymatic activity, leading to impaired tumor cell growth, enhanced immune responses, and induction of cell death. Moreover, CD38-targeted therapies have also been explored for autoimmune diseases and inflammatory disorders. Further research is underway to optimize CD38-targeted therapies and expand their applications in different disease settings.